Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170 000 participants in 26 randomised trials

The Lancet

Volumn 376, Issue 9753, 2010, Pages 1670-1681

  Baigent, C ^k,ad   Blackwell, L ^k   Emberson, J ^k   Holland, L E ^k   Reith, C ^k   Bhala, N ^k   Peto, R ^k,q,ac   Barnes, E H ^k   Keech, A ^k,m,q,v   Simes, J ^k,v   Collins, R ^k,q,ac,ad   De Lemos, J ^a   Braunwald, E ^a,k,ab   Blazing, M ^a   Murphy, S ^a,ab   Downs, J R ^b   Gotto, A ^b   Clearfield, M ^b   Holdaas, H ^c,h   Gordon, D ^d   Davis, B ^d   Koren, M ^e   Dahlof, B ^f   Poulter, N ^f   Sever, P ^f   Knopp, R H ^g   Fellstrom B ^h   Jardine, A ^h   Schmieder, R ^h   Zannad, F ^h   Goldbourt, U ⁱ   Kaplinsky, E ⁱ   Colhoun, H M ^j   Betteridge, D J ^j   Durrington, P N ^j   Hitman, G A ^j   Fuller, J ^j   Neil, A ^j   Wanner, C ^k   Krane, V ^k   Sacks, F ^l   Moye L ^l   Pfeffer, M ^l   Hawkins, C M ^k   Barter, P ^m   Tavazzi, L ⁿ   Maggioni, A ^n,o   Marchioli, R ^o   Tognoni, G ^o   Franzosi, M G ^o   Bloomfield, H ^p   Robins, S ^p   Armitage, J ^q,ac   Parish, S ^q,ac   Sleight, P ^q,ac   Pedersen, T R ^k,r   Ridker, P M ^s   Holman, R ^t   Meade, T ^u   MacMahon, S ^v   Marschner, I ^k,v   Tonkin, A ^v   Shaw, J ^v   Serruys, P W ^w   Nakamura, H ^x   Knatterud, G ^y   Furberg, C ^z   Byington, R ^z   Macfarlane, P ^aa,ag   Cobbe, S ^aa,ag   Ford, I ^aa,ag   Murphy, M ^aa   Blauw, G J ^aa   Packard, C ^aa   Shepherd, J ^aa,ag   Kjekshus, J ^k   Wilhelmsen, L ^k   Cannon, C ^ab   Bowman, L ^ac   Baxter, A ^k,ad   Landray, M ^ad   La Rosa, J ^ae   Rossouw, J ^af   Probstfield, J ^af   Flather, M ^k   Kastelein, J ^k   Newman, C ^k   Shear, C ^k   Tobert, J ^k   Varigos, J ^k   White, H ^k   Yusuf, S ^k   Mellies, M ^ah   McGovern, M ^ah   Barclay, J ^ah   Belder, R ^ah   Mitchel, Y ^ai   Musliner, T ^ai   Ansquer, J C ^aj   Llewellyn, M ^ak   Bortolini, M ^al   Brandrup Wognsen, G ^am   Bryzinski, B ^am   Olsson, G ^am   Pears, J ^am   De Micco, D ^an   Buck, G ^k   Herrington, W G ^k   Kearney, P M ^k   Kirby, A ^k   Lewis, D A ^k   Pollicino, C ^k   Sourjina, T ^k   more..

^a Phase Z   (United States)

^b AFCAPS TEXCAPS (AirForce Texas Coronary Atherosclerosis Prevention Study)   (United States)

^c ALERT (Assessment of Lescol in Transplantation)   (United States)

^d ALLHAT (Antihypertensive Lipid Lowering Heart Attack Trial)   (United States)

^e ALLIANCE (Aggressive Lipid Lowering Initiation Abates New Cardiac Events)   (United States)

^f ASCOT (Anglo Scandinavian Cardiac Outcomes Trial)   (United States)

^g ASPEN   (United States)

^h AURORA   (United States)

ⁱ BIP (Bezafibrate Infarction Prevention Study)   (United States)

^j CARDS (Collaborative Atorvastatin Diabetes Study)   (United States)

^k 4D ^*

^l CARE (Cholesterol and Recurrent Events Study)   (United States)

^m FIELD (Fenofibrate Intervention and Event Lowering in Diabetes)   (United States)

ⁿ GISSI (Gruppo Italiano per Lo Studio della Sopravvivenza nell'Infarto Miocardico) Heart Failure   (Italy)

^o GISSI Prevention   (Italy)

^p HIT (Veteran Administration Low HDL Intervention Trial)   (United States)

^q HPS (Heart Protection Study)   (United States)

^r IDEAL (Incremental Decrease in Endpoints Through Aggressive Lipid lowering)   (United States)

^s JUPITER   (United States)

^t LDS (Lipids in Diabetes Study)   (United States)

^u LEADER (Lower Extremity Arterial Disease Event Reduction Trial)   (United States)

^v LIPID (Long term Intervention with Pravastatin in Ischaemic Disease)   (United States)

^w LIPS (Lescol Intervention Prevention Study)   (United States)

^x MEGA (Management of Elevated Cholesterol in the Primary Prevention Group of Adult Japanese)   (United States)

^y Post CABG (Post Coronary Artery Bypass Graft Study)   (United States)

^z PPP (Pravastatin Pooling Project)   (United States)

^aa PROSPER   (United States)

^ab PROVE IT (Pravastatin or Atorvastatin Evaluation and Infection Therapy)   (United States)

^ac SEARCH (Study of Effectiveness of Additional Reductions in Cholesterol and Homocysteine)   (United States)

^ad SHARP (Study of Heart and Renal Protection)   (United States)

^ae TNT (Testing New Targets)   (United States)

^af WHI (Women's Health Initiative)   (United States)

^ag WOSCOPS (West of Scotland Coronary Prevention Study)   (United Kingdom)

^ah BRISTOL MYERS SQUIBB   (United States)

^ai MERCK RESEARCH LABORATORIES   (United States)

^aj Laboratoires Fournier   (United States)

^ak BAYER CORPORATION   (United States)

^al NOVARTIS PHARMA AG   (Switzerland)

^am ASTRAZENECA   (United Kingdom)

^an PFIZER INC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ABSENCE OF SIDE EFFECTS; ARTICLE; BRAIN ISCHEMIA; CANCER INCIDENCE; CANCER MORTALITY; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; DEATH; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; MORTALITY; PRIORITY JOURNAL; RANDOMIZATION; RISK REDUCTION; SYSTEMATIC REVIEW; TREATMENT DURATION;

EID: 78449281377     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(10)61350-5     Document Type: Article

References (49)

1. Cholesterol Treatment Trialists' (CTT) Collaborators Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins Lancet 366 2005 1267 1278
2. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
3. J Shepherd, SM Cobbe, I Ford Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia N Engl J Med 333 1995 1301 1307
4. FM Sacks, MA Pfeffer, LA Moyé The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators N Engl J Med 335 1996 1001 1009
5. The Post Coronary Artery Bypass Graft Trial Investigators The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts N Engl J Med 336 1997 153 162
6. JR Downs, M Clearfield, S Weis Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS JAMA 279 1998 1615 1622
7. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels N Engl J Med 339 1998 1349 1357
8. GISSI Prevenzione Investigators (Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico) Results of the low dose (20 mg) pravastatin GISSI Prevenzione trial in 4271 patients with recent myocardial infarction: do stopped trials contribute to overall knowledge? Ital Heart J 1 2000 810 820
9. PWJC Serruys, P de Feyter, C Macaya for the Lescol Intervention Study (LIPS) Investigators Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention JAMA 287 2002 3215 3222
10. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
11. J Shepherd, GJ Blauw, MB Murphy on behalf of the PROSPER study group Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
12. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care JAMA 288 2002 2998 3007
13. PS Sever, B Dahlof, NR Poulter Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm(ASCOT-LLA): a multicentre randomised controlled trial Lancet 361 2003 1149 1158 (Pubitemid 36398384)
14. H Holdaas, B Fellstrom, AG Jardine Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial Lancet 361 2003 2024 2031
15. HM Colhoun, DJ Betteridge, PN Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 2004 685 696
16. J Stamler, O Vaccaro, JD Neaton, D Werntworth Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial Diabetes Care 16 1993 434 444
17. Z Chen, R Peto, R Collins, S MacMahon, J Lu, W Li Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations BMJ 303 1991 276 282
18. Prospective Studies Collaboration Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55 000 vascular deaths Lancet 370 2007 1829 1839
19. MH Davidson, EA Stein, CA Dujovne The efficacy and six-week tolerability of simvastatin 80 and 160 mg/day Am J Cardiol 79 1997 38 42
20. TR Pedersen, JA Tobert Benefits and risks of HMG-CoA reductase inhibitors in the prevention of coronary heart disease: a reappraisal Drug Saf 14 1996 11 24
21. electronic Medicines Compendium Summary of product characteristics for atorvastatin http://medicines.org.uk/emc/document.aspx?documentid=1424 (accessed Aug 19, 2010).
22. electronic Medicines Compendium Summary of product characteristics for rosuvastatin http://medicines.org.uk/emc/document.aspx?documentid=11976 (accessed Aug 19, 2010).
23. JA de Lemos, MA Blazing, SD Wiviott Early intensive vs a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial JAMA 292 2004 1307 1316
24. CP Cannon, E Braunwald, CH McCabe Intensive versus moderate lipid lowering with statins after acute coronary syndromes N Engl J Med 350 2004 1495 1504
25. TR Pedersen, O Faergeman, JJ Kastelein High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial JAMA 294 2005 2437 2445
26. JC LaRosa, SM Grundy, DD Waters Intensive lipid lowering with atorvastatin in patients with stable coronary disease N Engl J Med 352 2005 1425 1435
27. Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial Lancet 2010 10.1016/S0140-6736(10) 60310-8 published online Nov 9.
28. CP Cannon, BA Steinberg, SA Murphy, JL Mega, E Braunwald Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy J Am Coll Cardiol 48 2006 438 445 (Pubitemid 44109954)
29. C Wanner, V Krane, W Marz Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis N Engl J Med 353 2005 238 248 (Pubitemid 41058323)
30. BC Fellstrom, AG Jardine, RE Schmieder for the AURORA Study Group Rosuvastatin and cardiovascular events in patients undergoing hemodialysis N Engl J Med 360 2009 1395 1407
31. GISSI-HF investigators Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 2008 1231 1239
32. J Kjekshus, E Apetrei, V Barrios for the CORONA Group Rosuvastatin in older patients with systolic heart failure N Engl J Med 357 2007 2248 2261
33. The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators High-dose atorvastatin after stroke or transient ischemic attack N Engl J Med 355 2006 549 559
34. AA Alsheikh-Ali, PV Maddukuri, H Han, RH Karas Effect of the magnitude of lipid-lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials J Am Coll Cardiol 50 2007 409 418
35. O Ben-Yehuda, AN DeMaria Low LDL-C levels and cancer: reassuring but still not definitive J Am Coll Cardiol 52 2008 1150 1151
36. Cholesterol Treatment Trialists' (CTT) Collaboration Protocol for a prospective collaborative overview of all current and planned randomized trials of cholesterol treatment regimens. Cholesterol Treatment Trialists' (CTT) Collaboration Am J Cardiol 75 1995 1130 1134
37. H Nakamura, K Arakawa, H Itakura for the MEGA Study Group Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial Lancet 368 2006 1155 1163
38. PM Ridker, E Danielson, FAH Fonseca for the JUPITER Study Group Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
39. MJ Koren, DB Hunninghake Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study J Am Coll Cardiol 44 2004 1772 1779
40. RH Knopp, M d'Emden, JG Smilde, SJ Pocock Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN) Diabetes Care 29 2006 1478 1485
41. VG Athyros, AA Papageorgiou, BR Mercouris Treatment with atorvastatin to the National Cholesterol Education Program goal versus 'usual' care in secondary coronary heart disease prevention. The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study Curr Med Res Opin 18 2002 220 228
42. PM Ridker, J Genest, SM Boekholdt for the JUPITER Trial Study Group HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial Lancet 376 2010 333 339
43. H Iso, DR Jacobs Jr, D Wentworth, JD Neaton, JD Cohen Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the Multiple Risk Factor Intervention Trial N Engl J Med 320 1989 904 910
44. LB Goldstein Low LDL cholesterol, statins, and brain hemorrhage: should we worry? Neurology 68 2007 719 720
45. SM Grundy, JI Cleeman, CNB Merz Implications of recent trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
46. NICE Clinical Guideline 67 Lipid modification: cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease 2008 National Institute for Health and Clinical Excellence London
47. J Armitage The safety of statins in clinical practice Lancet 370 2007 1781 1790
48. M Davidson, JG Robinson Safety of aggressive lipid management J Am Coll Cardiol 49 2007 1753 1762
49. R Ara, A Pandor, J Stevens, A Rees, R Rafia Early high-dose lipid-lowering therapy to avoid cardiac events: a systematic review and economic evaluation Health Technol Assess 13 2009 1 74 75-118.